Excellent outcomes were described after using endorectal high-dose-rate (HDR) brachytherapy boost in the non-operative management of rectal cancer.
However, evidence regarding this strategy remains limited.
The NOM-3 prospective single-centre cohort study aimed to evaluate whether the outcomes of this strategy would match those reported by others.
